---

Market Overview

---

The global market for atopic dermatitis treatment was valued at USD 4.85 billion in 2021 and is projected to reach USD 11.34 billion by 2027, growing at a CAGR of 15.20% from 2022 to 2027. Atopic dermatitis, also known as atopic eczema, is a chronic inflammatory skin condition characterized by itching and inflammation. It commonly affects the face, neck, arms, and legs, but not the groin and axillary regions. People of all ages, from newborns to adults over 65 years old, can develop atopic dermatitis. This condition is associated with an increased risk of comorbidities such as food allergy, asthma, allergic rhinitis, and mental health disorders, contributing to the growth of the atopic dermatitis treatment market.

Atopic dermatitis is the most prevalent type of eczema, affecting approximately 26 million people in the United States. In children, the prevalence of atopic dermatitis has been steadily increasing from 8% to 12% over the past two decades. The condition is characterized by a defect in the skin barrier, allowing allergens and irritants to enter and trigger an immune reaction and inflammation. This leads to the development of a red, itchy rash, primarily on the face, arms, and legs, which can cover large areas of the body. The itching can result in damage caused by scratching, perpetuating a cycle of itching and scratching. Pediatric patients with atopic dermatitis may experience sleep disturbances, behavioral problems, and interference with normal childhood activities. Adults also experience sleep disturbances, emotional impacts, and impaired social functioning. China, the United States, and Japan have high prevalent cases of atopic dermatitis, driving the growth of the market.

The exact cause of atopic dermatitis is unknown, and there are no specific biomarkers or laboratory findings to definitively diagnose the condition. Diagnosis is based on the patient’s medical history and physical examination, with investigation into possible exacerbating factors such as allergens, irritating chemicals, foods, and emotional stress.

Topical therapies, particularly low to mid-potency topical steroids and topical calcineurin inhibitors, are commonly used to treat atopic dermatitis. However, these therapies have limitations. Prolonged use of topical steroids can damage the skin and worsen itching. Topical calcineurin inhibitors provide less symptomatic improvement and are associated with application site burning. Some systemic treatments, such as biologics and JAK inhibitors, are also used for more severe cases of atopic dermatitis.

In the clinical trial landscape, there are currently over 153 trials in various phases of development for atopic dermatitis. Most industry-sponsored drugs are in Phase II, indicating ongoing research and development in this field. Biological therapies, such as anti-interleukin antibodies, are widely used, and there is a demand for therapies with novel mechanisms of action that are less immunogenic. Several new agents, including interleukin inhibitors, topical JAK inhibitors, and topical phosphodiesterase 4 inhibitors, are expected to enter the market in the near future, creating growth opportunities.

Overall, there is a growing market for atopic dermatitis treatment, driven by the increasing prevalence of the condition and the need for more effective therapies. Innovation and advancements in research and development are expected to bring improvements in treatment outcomes and expand the evidence base for interventions.

---

Market Segmentation

---

The market is segmented based on various factors, including drug class, gender type, age group, severity type, and geography.

Segmentation by Drug Class
Topical Steroids
Topical Calcineurin Inhibitors
Other Class of Drugs

Segmentation by Gender Type
Men
Women

Segmentation by Age Group
18 years and Below
19 years and Above

Segmentation by Severity Type
Moderate
Mild
Severe

Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan

Drug Class: Topical steroids are projected to hold a significant share in the global atopic dermatitis treatment market within the drug class segment. However, the other drug class is expected to experience the highest growth rate during the forecast period. The recent approvals of JAK and interleukin inhibitors are anticipated to drive the global atopic dermatitis therapeutics market throughout the forecast period.

Gender Type: Women are expected to dominate the global atopic dermatitis treatment market in terms of gender type. This can be attributed to the heightened risk of atopic dermatitis among women in recent years.

Age Group: Individuals aged 19 years and above are projected to account for the largest portion of the global atopic dermatitis market share within the age group segment.

Severity Type: Among the different severity types, those with mild forms are anticipated to hold a significant share of the global market. However, individuals with moderate forms are expected to exhibit the highest growth rate during the forecast period.

In North America, the United States currently holds the dominant position in the global atopic dermatitis treatment market. This can be attributed to increased healthcare affordability, growing knowledge and awareness among the population, and advancements in technology within this region. However, Japan is expected to witness rapid growth with a high compound annual growth rate (CAGR) in the atopic dermatitis drug market. This growth is driven by improved access to and quality of healthcare, increased awareness about disease management, and rising healthcare expenditures in the region.

---

Competitive Landscape

---

The global atopic dermatitis treatment market is characterized by the presence of numerous companies offering generic drugs, as well as selective pharmaceutical and biotechnology companies providing patented and commercial drugs for the treatment of atopic dermatitis. In 2017, the U.S. Food and Drug Administration (FDA) approved Dupixent (Dupilumab), an interleukin antibody, for the treatment of atopic dermatitis, which marked the introduction of interleukin biologics in this treatment landscape. More recently, the FDA approved other interleukins such as Tralokinumab-idrm (adbry) in 2021, and Mitchga (Nemolizumab) was approved by the PMDA in 2022 for the treatment of atopic dermatitis. While generic products continue to hold significant market share in atopic dermatitis treatment, the emergence of biologics and targeted therapies indicates a shift in the therapeutic approach throughout the projected period.

New therapeutics under development for atopic dermatitis include Lebrikizumab, CM-310, Tapinarof, Roflumilast, Rocatinlimab, and others. The introduction of these novel emerging drugs will soon bring about a paradigm shift in atopic dermatitis treatment. With over 153 molecules in various stages of development, it is anticipated that new vendors will enter the market with innovative mechanisms of action and improved safety and efficacy profiles compared to existing patented commercial drugs used for atopic dermatitis treatment.

Leading players in the global atopic dermatitis treatment market include AbbVie, Pfizer, Novartis, LEO Pharma, Sanofi/Regeneron, Incyte Corp, Maruho Co., Ltd, Eli Lilly and Company, Japan Tobacco Inc, and others. These companies are actively implementing growth strategies to enhance their product portfolios. These strategies involve collaborations, acquisitions, geographical expansion, investments in research and development, and the development of novel drugs to strengthen their competitiveness in the global atopic dermatitis treatment market. Other notable players operating in the market include Arcutis Biotherapeutics, Kyowa Hakko Kirin, Dermavant Sciences, Vanda Pharmaceuticals, CARA Therapeutics, and several others.

Key companies profiled in this report include LEO Pharma, Pfizer, Sanofi/Regeneron, Novartis, Incyte Corp, AbbVie, Eli Lilly and Company, Japan Tobacco Inc, Maruho Co., Ltd, Otsuka Holdings Co Ltd, Astellas Pharma Inc, Stiefel Laboratories, Arcutis Biotherapeutics, Kyowa Hakko Kirin, Vanda Pharmaceuticals, Dermavant Sciences, CARA Therapeutics, AstraZeneca Plc (AstraZeneca), UNION therapeutics, Asana, Evelo Biosciences, BiomX, AOBiome Therapeutics, Inc., Amytrx, RAPT Therapeutics, Oneness Biotech, VYNE’s Therapeutics, BenevolentAI Ltd, vTv Therapeutics Inc., Botanix Pharmaceuticals Ltd (BOT), selectION, Inc., Inmagene, Novan, Inc.

---

Key Questions Answered

---

What is the expected size of the global atopic dermatitis treatment market?
The estimated size of the global atopic dermatitis treatment market is projected to reach USD 11.34 billion by 2027.

What is the growth rate of the global atopic dermatitis treatment market?
The global atopic dermatitis treatment market is experiencing a compound annual growth rate (CAGR) of 15.20% from 2022 to 2027.

What are the key drivers of growth in the atopic dermatitis treatment market?
The growth of the atopic dermatitis treatment market is primarily driven by factors such as the increasing demand for biologics, the growing burden of allergic reactions, and the anticipated launch of emerging drugs.

Who are the major vendors operating in the global atopic dermatitis treatment market?
The key players in the global atopic dermatitis treatment market include LEO Pharma, Pfizer, Sanofi/Regeneron, Novartis, Incyte Corp, AbbVie, Eli Lilly and Company, Japan Tobacco Inc, Maruho Co., Ltd, Otsuka Holdings Co Ltd, Astellas Pharma Inc, and Stiefel Laboratories.

Which region holds the largest market share in the global atopic dermatitis treatment market?
North America, particularly the United States, dominates the global atopic dermatitis treatment market. This can be attributed to factors such as increased healthcare affordability, higher knowledge and awareness among the population, and advancements in technology within the region.